Please assess the completion status of the following clinical trial:

Trial Title: Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 9.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females, between 18 and 75 years of age, inclusive~* Histologically confirmed NASH diagnosis~Exclusion Criteria:~* Clinically significant acute or chronic liver disease~* Prior liver transplantation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 - Placebo (Type: PLACEBO_COMPARATOR): Cohort 1 - Placebo
- Cohort 1 - NGM282 3mg (Type: EXPERIMENTAL): Cohort 1 - NGM282 3mg
- Cohort 1 - NGM282 6mg (Type: EXPERIMENTAL): Cohort 1 - NGM282 6mg
- Cohort 2 - NGM282 0.3mg (Type: EXPERIMENTAL): Cohort 2 - NGM282 0.3mg
- Cohort 2 - NGM282 1mg (Type: PLACEBO_COMPARATOR): Cohort 2 - NGM282 1mg
- Cohort 2 - NGM282 3mg (Type: EXPERIMENTAL): Cohort 2 - NGM282 3mg
- Cohort 3 - NGM282 1mg (Type: EXPERIMENTAL): Cohort 3 - NGM282 1mg
- Cohort 4 - Placebo (Type: PLACEBO_COMPARATOR): Cohort 4 - Placebo
- Cohort 4 - NGM282 1mg (Type: EXPERIMENTAL): Cohort 4 - NGM282 1mg

Based on this trial design, predict the completion outcome and termination type (if applicable).